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adenosine monophosphate (cAMP) seems 
to be the culprit in this process. This second 
messenger is antiproliferative in normal epi-
thelial cells, but it increases the proliferation 
of the mutant cells. Low cell calcium seems 
to be involved in this process as well, since 
blockade of calcium channels into normal 
cells causes cAMP-dependent mitogenesis. 
Much of this information was developed in 
vitro with the use of cells taken from human 
or mouse models of PKD. Nagao et al. 
studied the mechanism in vivo in the Cy/+ 
PKD rat, a model of the dominant variety 
of PKD, before and after treatment with the 
calcium channel blocker verapamil. Treat-
ment increased kidney weight and enlarged 
cysts, which was associated with more cell 
proliferation and apoptosis, and increased 
signaling through the mitogen-activated 
protein kinases. Verapamil had no eﬀect on 
kidney morphology in wild-type rats. These 
ﬁndings show that calcium channel block-
ers accelerate cyst growth in the presence of 
endogenous cAMP, thus exacerbating PKD. 
See page 269.
Calcimimetics and 
vascular calcification
Soft-tissue calciﬁcation is emerging as a 
serious consequence of hyperparathy-
roidism seen in renal failure. In a new 
study, Lopez et al. show the eﬀect of treat-
ing uremic rats with vitamin D derivatives 
(calcitriol or paricalcitol) or with blockers 
of the calcium-sensing receptor (calcimi-
metics). A new calcimimetic, AMG 641, 
was used alone or in combination with 
vitamin D derivatives. After the induction of 
renal failure, all animals developed second-
ary hyperparathyroidism. Treatment with 
the calcimimetic or vitamin D analogues 
reduced parathyroid hormone levels as 
Dose–response curve 
of epoetin in dialysis 
patients
Most patients on hemodialysis receive 
erythropoietin (epoetin) to treat anemia, 
yet the dose–response curve for the treat-
ment has not been examined in a detailed 
manner. It is not practical to study large 
numbers of patients on hemodialysis to 
provide a rigorous pharmacological study. 
Hence, many previous studies have relied 
on administrative databases. Also, many 
clinicians give patients with the lowest 
hematocrits (of whatever cause) the larg-
est amount of epoetin. This confounding 
factor was eliminated in a study reported 
in this issue. Cotter et al. used a ‘marginal 
structural’ model adjusting for the time-
dependent inﬂuence of the indication for 
treatment. Using the United States Renal 
Data System to monitor older patients who 
started dialysis and epoetin treatment, the 
authors found that the hematocrit response 
to average weekly epoetin doses showed an 
S-shaped dose–response relationship. The 
dose required to maintain a given hema-
tocrit was lower than that to induce the 
same change at initiation of therapy. The 
dose–response curve found in this study 
suggests that published recommendations 
for a starting dose of epoetin are appropri-
ate; a starting dose of 7,500–15,000 units 
per week can maintain the hematocrit level 
in the desired target range of 33%–36%. 
See page 347.
Calcium channel 
inhibition and PKD
Cells lining the cysts of polycystic kidney 
disease (PKD) are less diﬀerentiated and 
proliferate more than normal, terminally 
diﬀerentiated tubular epithelial cells. Cyclic 
expected, but treatment with a combina-
tion of calcimimetic and paricalcitol was 
most eﬀective. Vitamin D analogue treat-
ment increased aortic calciﬁcation, whereas 
calcimimetic treatment did not lead to 
extraskeletal calciﬁcation. Vitamin D ana-
logue treatment resulted in a higher mortal-
ity, which was blunted by coadministration 
of the calcium receptor blocker. When used 
in combination with paricalcitol, AMG 641 
provided excellent control of secondary 
hyperparathyroidism and prevented mor-
tality associated with the use of vitamin D 
derivatives without causing tissue calciﬁca-
tion. See page 300.
Heparanase and 
anionic sites
Fixed negative charges in the glomerular 
basement membranes are a classic deter-
rent to the passage of albumin across the 
ﬁltration barrier. It has been shown that 
many of these fixed charges are due to 
heparan sulfate proteoglycans. Further, 
in a number of diseases associated with 
proteinuria,  there is increased expression 
of heparanase in the glomerulus. Since it 
is an enzyme, heparanase is expected to 
reduce the negative charges by degrading 
the heparan sulfate proteoglycans. In a new 
study, mice that transgenically overexpress 
heparanase were examined. Remarkably, 
no change occurred in the morphology 
or function in these animals, especially 
proteinuria. Yet the majority of the gly-
cosaminoglycans were removed. Although 
some heparanase-resistant anionic sites 
may exist, the study does demonstrate the 
complexity of measuring these anionic 
sites. An excellent Commentary by Morita 
et al. addresses the methodological issues 
of measuring anionic sites. See page 247.
